The collaboration aims to make home-based Alzheimer’s biomarker testing more accessible through virtually painless blood collection technology.
Neurogen Biomarking has entered a partnership agreement with Tasso Inc to integrate Tasso’s needle-free blood collection technology into Neurogen’s home-based Alzheimer’s testing platform.
The collaboration positions Neurogen to build a scalable, home-based model for Alzheimer’s-related biomarker testing and cognitive-health services. Neurogen’s testing ecosystem will incorporate Tasso’s patient-centric collection devices to enable comfortable blood sample collection, expanding equitable access to Alzheimer’s-related biomarker testing.
Neurogen’s platform combines a blood-based biomarker test with a digital cognitive assessment to help identify individuals who may be at higher risk for Alzheimer’s disease. Licensed blood collection specialists visit patients at home to obtain samples using the Tasso+ device alongside traditional draws. Samples are processed in certified laboratories, and results are reviewed by board-certified neurologists via telehealth.
“Neurogen is on a fast-track to becoming the global entry point for early evaluation of Alzheimer’s-related biomarkers,” says Dr Rany Aburashed, chief executive officer and founder of Neurogen Biomarking, in a release. “The addition of Tasso’s technology to our ecosystem creates a streamlined, scalable at-home experience designed to make Alzheimer’s-related testing more accessible.”
Research Validates Sample Quality
Research presented at the 2025 Alzheimer’s Association International Conference demonstrated that Tasso’s blood collection system provided sample quality suitable for Alzheimer’s biomarker analysis. The study, “Remote Collection of Biomarkers for Alzheimer’s Disease and Related Disorders,” was presented by Elisabeth Thijssen, PhD, chief scientific officer at Neurogen Biomarking.
The research highlighted Neurogen’s integrated approach that merges in-home biomarker collection, cognitive assessment, and virtual neurological consultation. Findings suggest the platform could help reduce delays in accessing cognitive-health evaluation. The study also found a strong correlation between samples collected via Tasso versus traditional venipuncture, supporting Tasso’s use within Neurogen’s workflow.
“Making blood collection more patient-centric is key to ensuring everyone who needs testing has access to it,” says Ben Casavant, PhD, chief executive officer and co-founder of Tasso, in a release. “Our virtually painless collection technology offers individuals a simple and comfortable way to provide blood samples.”
Addressing Diagnostic Delays
Studies show patients often wait 45 to 50 months from their initial primary care visit to their first neurology appointment. The current standard of care delays Alzheimer’s diagnosis by several years. Currently it takes five to seven years between symptom onset and diagnosis, but with the Neurogen platform it can take as short as five to seven months.
An estimated 40% of Americans aged 65 and older—more than 16 million people—experience some form of memory impairment. Yet fewer than 8% of older adults with Mild Cognitive Impairment ever receive a formal diagnosis, leaving 92% without answers or access to early intervention. Moreover, fewer than one in five Alzheimer’s diagnoses in the US currently involve biomarker testing, largely due to accessibility and expertise gaps.
Neurogen’s online platform, offering at-home Alzheimer’s biomarker collection for individuals with memory concerns, is currently in beta testing. The company offers the first at-home blood biomarker test for phosphorylated tau (P-tau217), paired with digital cognitive testing and neurologist-guided telehealth results.
Photo caption: Neurogen Biomarking enters partnership agreement with Tasso to bring virtually painless blood collection technology to Its Alzheimer’s testing platform
Photo credit: Neurogen Biomarking
